Business Context and Reporting Period
This Form 8-K is a current report filed by NanoVibronix, Inc. (not Envue Medical, Inc.) on December 19, 2024. The filing documents the results of the Company's 2024 Annual Meeting of Stockholders held on the same date. The Company is incorporated in Delaware and its common stock trades on the Nasdaq Capital Market under the symbol NAOV.
Key Financial Metrics
This filing is a corporate governance report and does not contain financial performance data. There are no disclosures regarding revenue, profit, cash flow, margins, debt, or liquidity in this document.
Material Changes and Voting Results
As of the record date (October 28, 2024), there were 3,752,354 shares of common stock outstanding. Approximately 2,046,820 votes were present at the meeting. All five proposals submitted to stockholders were approved:
- Election of Directors: Eight nominees were elected to the Board of Directors for a one-year term. Voting results showed significant support, with "For" votes ranging from 668,461 to 685,652 per nominee. Notably, there were 1,146,998 broker non-votes for each director nominee.
- Ratification of Auditor: Stockholders ratified the appointment of Zwik CPA, PLLC as the independent registered public accounting firm for the fiscal year ending December 31, 2024 (2,006,926 For vs. 25,623 Against).
- 2024 Long-Term Incentive Plan: The plan was approved (635,057 For vs. 262,753 Against). The full text of the plan is filed as Exhibit 10.1.
- Advisory Vote on Executive Compensation: The "Say-on-Pay" proposal was approved (629,513 For vs. 265,874 Against).
- Adjournment Proposal: Approved to allow for further proxy solicitation if necessary, though no adjournment was ultimately required.
Guidance, Outlook, and Risks
The filing does not provide management commentary, financial guidance, or an outlook for future periods. It does not disclose specific risks or contingencies beyond the standard incorporation by reference of the Proxy Statement for details on the Incentive Plan.
Investor Verification Checklist
- Verify the company name is NanoVibronix, Inc. (NAOV), as the input metadata incorrectly referenced "Envue Medical, Inc."
- Review the definitive Proxy Statement (Schedule 14A) filed on October 29, 2024, for detailed terms of the approved 2024 Long-Term Incentive Plan.
- Note the high volume of broker non-votes (1,146,998) on director elections and the advisory compensation vote, indicating a significant portion of shares held by brokers did not receive instructions.
- Confirm the appointment of Zwik CPA, PLLC as the new independent auditor for the 2024 fiscal year.